Total submissions: 10
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV001704918 | SCV000237523 | likely benign | not provided | 2018-10-12 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000643177 | SCV000764864 | uncertain significance | Dilated cardiomyopathy 1G; Autosomal recessive limb-girdle muscular dystrophy type 2J | 2017-11-02 | criteria provided, single submitter | clinical testing | |
ARUP Laboratories, |
RCV000184805 | SCV001157846 | uncertain significance | not specified | 2018-09-26 | criteria provided, single submitter | clinical testing | The TTN c.65599C>T; p.Arg21867Cys variant (rs200028088; ClinVar Variation ID: 202847) is rare in the general population (<1% allele frequency in the Genome Aggregation Database) and has not been reported in the medical literature in association with dilated cardiomyopathy (DCM) or other TTN-related disease. The clinical relevance of rare missense variants in this gene, which are identified on average once per individual sequenced in affected populations (Herman 2012), is not well understood. Yet, evidence suggests that the vast majority of such missense variants do not contribute to the clinical outcome of DCM (Begay 2015). Thus, the clinical significance of the p.Arg21867Cys variant cannot be determined with certainty. |
Centre for Mendelian Genomics, |
RCV001197045 | SCV001367680 | uncertain significance | See cases | 2020-03-17 | criteria provided, single submitter | clinical testing | This variant was classified as: Uncertain significance. The available evidence on this variant's pathogenicity is insufficient or conflicting. The following ACMG criteria were applied in classifying this variant: PM2,PP3. |
Ambry Genetics | RCV002336483 | SCV002637763 | uncertain significance | Cardiovascular phenotype | 2018-01-16 | criteria provided, single submitter | clinical testing | The p.R15370C variant (also known as c.46108C>T), located in coding exon 153 of the TTN gene, results from a C to T substitution at nucleotide position 46108. The arginine at codon 15370 is replaced by cysteine, an amino acid with highly dissimilar properties. This amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Revvity Omics, |
RCV001704918 | SCV003818431 | uncertain significance | not provided | 2023-08-03 | criteria provided, single submitter | clinical testing | |
Ce |
RCV001704918 | SCV004150290 | uncertain significance | not provided | 2022-11-01 | criteria provided, single submitter | clinical testing | |
Mayo Clinic Laboratories, |
RCV001704918 | SCV004225817 | uncertain significance | not provided | 2023-05-17 | criteria provided, single submitter | clinical testing | |
Joint Genome Diagnostic Labs from Nijmegen and Maastricht, |
RCV001704918 | SCV001979648 | uncertain significance | not provided | no assertion criteria provided | clinical testing | ||
Clinical Genetics DNA and cytogenetics Diagnostics Lab, |
RCV001704918 | SCV001980483 | uncertain significance | not provided | no assertion criteria provided | clinical testing |